Advocating for Demonstration of Disease Modification—Have We Been Approaching Clinical Trials in Early Alzheimer Disease Incorrectly?

Trial of Cinpanemab in Early Parkinson’s Disease

(2022) Anthony E. Lang et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects

(2022) N. Villain et al.   REVUE NEUROLOGIQUE

Lecanemab in Early Alzheimer’s Disease

(2022) Christopher H. van Dyck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Donanemab in Early Alzheimer’s Disease

(2021) Mark A. Mintun et al.   NEW ENGLAND JOURNAL OF MEDICINE

Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype

(2019) Lisa Vermunt et al.   Alzheimers & Dementia

The Cellular Phase of Alzheimer’s Disease

(2016) Bart De Strooper et al.   CELL